Frank Erhard Uschner
Overview
Explore the profile of Frank Erhard Uschner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
737
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trebicka J, Aguilar F, Farias A, Lozano J, Sanchez-Garrido C, Uson-Raposo E, et al.
Gut
. 2025 Feb;
PMID: 40011033
Background And Aims: Quantifying systemic inflammation (SI) in acutely decompensated cirrhosis (ADC) is of major importance because SI is a driver of the most severe forms of ADC, including acute-on-chronic...
2.
Pose E, Jimenez C, Zaccherini G, Campion D, Piano S, Uschner F, et al.
JAMA
. 2025 Feb;
333(10):864-874.
PMID: 39908052
Importance: There are no useful treatments to prevent the development of severe complications of liver cirrhosis. Simvastatin and rifaximin have shown beneficial effects in liver cirrhosis. Objective: To assess whether...
3.
Trebicka J, Praktiknjo M, Peiffer K, Pascher A, Schulz M, Uschner F
Dtsch Arztebl Int
. 2025 Jan;
Forthcoming.
PMID: 39773823
Background: Cirrhosis is the end stage of chronic liver disease. Cirrhosis causes portal hypertension, which, in turn, can lead to acute on chronic liver failure (ACLF), which is defined as...
4.
Kraus N, Uschner F, Moeslein M, Schierwagen R, Gu W, Brol M, et al.
Cells
. 2024 Oct;
13(20.
PMID: 39451225
Metabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models...
5.
Gu W, de Ledinghen V, Aube C, Krag A, Strassburg C, Castera L, et al.
NEJM Evid
. 2024 Oct;
3(11):EVIDoa2400062.
PMID: 39437136
Background: Patients with advanced chronic liver disease (ACLD) are at high risk of developing hepatocellular carcinoma (HCC). Therefore, biannual surveillance is recommended. This large-scale multicenter study aimed to stratify the...
6.
Brol M, Drebber U, Yu X, Schierwagen R, Gu W, Plamper A, et al.
Surg Obes Relat Dis
. 2024 Mar;
20(8):759-766.
PMID: 38522962
Background: Obesity and nonalcoholic fatty liver disease (NAFLD) are an increasing health care burden worldwide. Weight loss is currently the best option to alleviate NAFLD and is efficiently achieved by...
7.
Mucke M, Hernandez-Tejero M, Gu W, Kuhn M, Janz M, Keller M, et al.
Aliment Pharmacol Ther
. 2024 Feb;
59(7):877-888.
PMID: 38414095
Background: Patients with cirrhosis are susceptible to develop bacterial infections that trigger acute decompensation (AD) and acute-on-chronic liver failure (ACLF). Infections with multidrug-resistant organisms (MDRO) are associated with deleterious outcome....
8.
Bartimoccia S, Praktiknjo M, Nocella C, Schierwagen R, Cammisotto V, Jansen C, et al.
Intern Emerg Med
. 2024 Feb;
19(3):713-720.
PMID: 38409619
Pathophysiology of portal vein thrombosis (PVT) in cirrhosis is still not entirely understood. Elevated levels of lipopolysaccharides (LPS) in portal circulation are significantly associated with hypercoagulation, increased platelet activation and...
9.
Mucke M, El Bali N, Schwarzkopf K, Uschner F, Kraus N, Eberle L, et al.
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38338821
Acute-on-chronic liver failure (ACLF) is associated with increased mortality. Specific therapy options are limited. Hypoxia-inducible factor 1 alpha (HIF-1α) has been linked to the pathogenesis of chronic liver disease (CLD),...
10.
Ruiz-Margain A, Pohlmann A, Lanzerath S, Langheinrich M, Campos-Murguia A, Roman-Calleja B, et al.
JHEP Rep
. 2023 Aug;
5(8):100761.
PMID: 37554924
Background & Aims: Acute-on-chronic liver failure (ACLF) has been linked to different pathophysiological mechanisms, including systemic inflammation and mitochondrial dysfunction. Sarcopenia has also been proposed as a potential mechanism; myostatin...